Autolus Taps Markets After CAR-T Success In Pivotal Leukemia Trial
Touts Differentiated Safety Profile
Executive Summary
The UK firm’s obe-cel has met the primary endpoint in a Phase II acute lymphocytic leukemia trial, triggering filing plans and a $150m public offering as observers commend the drug’s competitive safety profile.